24 September 2024 in Journal of Antimicrobial Chemotherapy
Translation of experimental data on antibiotic activity typically relies on pharmacokinetic/pharmacodynamic (PK/PD) indices. Model-based approaches, considering the full antibiotic killing time course, could be an alternative. To develop a mechanism-based modelling framework to assess the in vitro and in vivo activity of the FabI inhibitor antibiotic afabicin, and explore the ability of a model built on in vitro data to predict in vivo outcome. A PK/PD model was built to describe bacterial counts from 162 static in vitro time–kill curves evaluating the effect of afabicin desphosphono, the active moiety of the prodrug afabicin, against 21 Staphylococcus aureus strains. Combined with a mouse PK model, outcomes of afabicin doses of 0.011–190 mg/kg q6h against nine S. aureus strains in a murine thigh infection model were predicted, and thereafter refined by estimating PD parameters. A sigmoid Emax model, with EC50 scaled by the MIC described the afabicin desphosphono killing in vitro. This model predicted, without parameter re-estimation, the in vivo bacterial counts at 24 h within a ±1 log margin for most dosing groups. When parameters were allowed to be estimated, EC50 was 38%–45% lower in vivo, compared with in vitro, within the studied MIC range. The developed PK/PD model described the time course of afabicin activity across experimental conditions and bacterial strains. This model showed translational capacity as parameters estimated on in vitro time–kill data could well predict the in vivo outcome for a wide variety of doses in a mouse thigh infection model.
17 November 2024 in International Journal of Antimicrobial Agents
Carbapenem-resistant bacteria pose a threat to public health. Characterizing the pharmacokinetics-pharmacodynamics (PKPD) of meropenem longitudinally in vivo against resistant bacteria could provide valuable information for development and translation of carbapenem-based therapies. To assess the time course of meropenem effects in vivo against strains with high MIC to predict PK/PD indices and expected efficacy in patients using a modelling approach. A PKPD model was built on longitudinal bacterial count data to describe meropenem effects against six Escherichia coli and Klebsiella pneumoniae strains (MIC values 32-128 mg/L) in a 24h mouse thigh infection model. The model was used to derive PK/PD indices from simulated studies in mice and to predict the efficacy of different infusion durations with high-dose meropenem (2 g q8h/q12h for normal/reduced kidney function) in patients. Data from 592 mice were available for model development. The estimated meropenem concentration-dependent killing rate was not associated with differences in MIC. The fraction of time that unbound concentrations exceeded EC50 (fT>EC50, EC50=1.01 mg/L) showed higher correlations than fT>MIC. For all investigated strains, bacteriostasis at 24h was predicted for prolonged infusions of high-dose meropenem monotherapy in >90% of patients. The developed PKPD model successfully described bacterial growth and meropenem killing over time in the thigh infection model. For the investigated strains the MIC, determined in vitro, or MIC-based PK/PD indices, did not predict in vivo response. Simulations suggested prolonged infusions of high-dose meropenem to be efficacious in patients infected by the studied strains.
1 April 2026 in Antimicrobial Agents and Chemotherapy
In vivo antibiotic pharmacokinetic-pharmacodynamic (PKPD) properties are typically studied in neutropenic infection models, limiting the understanding of interactions between immune cells and antibiotics. This study aimed to characterize the impact of immune status on meropenem PKPD and dose-response in a mouse lung infection model, and to quantify the relative contribution of immune response and meropenem to bacterial killing. Meropenem PK was analyzed in plasma and epithelial lung fluid, and bacterial counts were monitored over 24 h following 40 or 300 mg/kg meropenem doses every 4 h in a mouse lung infection model with varying immunosuppression levels (neutropenic, intermediate, or immunocompetent). A PKPD model was developed to quantify bacterial killing by the immune response and meropenem over time. Dose-fractionation studies were simulated to investigate meropenem dose-response in different immune states. Observed differences in meropenem concentration-time profiles were explained by a higher volume of distribution in immunocompetent mice. The immune response was described by phagocytosis and digestion processes. The meropenem effect was best quantified based on plasma concentrations, with a maximal killing rate of 0.934 h −1 and EC 50 = 1.62 mg/L. The lower contribution of meropenem to bacterial killing in intermediate and immunocompetent conditions was explained as a lower fraction of bacteria being affected by meropenem. In simulations, the immune status impacted PKPD target derivation. The developed model characterized differences in meropenem PK between neutropenic and immunocompetent in vivo infection models and quantified the contributions of immune response and meropenem to bacterial killing, with a reduced effect of meropenem in immunocompetent systems.
4 March 2025 in JAC-Antimicrobial Resistance
Objectives: To evaluate the impact of antibiotic dose fractionation study design on pharmacokinetic/pharmacodynamic (PK/PD) indices and PKPD model estimation. Methods: PKPD models for meropenem and polymyxin B (PMB) were applied to (i) simulate various dose fractionation studies in mice to derive PK/PD indices and efficacy targets and (ii) perform stochastic simulations and estimations evaluating which efficacy assessment times, in addition to 24 h, would improve the estimation of drug effect parameters. Results: The R2 values of PK/PD indices were primarily influenced by reductions of the dosing intervals for meropenem and by decreases of the lowest total daily dose for PMB. For certain study designs (e.g. frequent administration of higher meropenem doses), R2 values for fT > MIC and fAUC/MIC were similar. Efficacy target magnitudes were also sensitive to the selected doses. Additional efficacy assessment times improved parameter accuracy (e.g. 40% reduction in relative root mean squared error of PMB effect slope). The model parameter accuracy was more affected by the selection of time points for meropenem, which included resistance, than for PMB. Efficacy measurements in the first hours after treatment start (e.g. 2 and 6 h), in addition to 24 h, were essential for resistance characterization. Conclusions: The choice of doses and fractionations impacted PK/PD index selection and efficacy target magnitude. Depending on the antibiotic, the dose or fractionation selection appeared to be the most critical. Early treatment efficacy measurements were beneficial to PKPD model-based analyses, particularly to describe resistance processes.
1 April 2026 in Antimicrobial Agents and Chemotherapy
This study aimed to describe the immune response and activity of the novel antibiotic afabicin against Staphylococcus aureus in an immunocompetent mouse thigh infection model using PKPD modeling and to predict the clinical efficacy of different afabicin dosing regimens in Staphylococcus -infected immunocompetent patients. Bacterial counts of five Staphylococcus aureus strains were determined over 74 h in an immunocompetent mouse thigh infection model. Afabicin doses of 0.011–150 mg/kg were administered intraperitoneally every 6 h. A PKPD model was developed to describe immune response and afabicin desphosphono (active moiety) activity. The model was used jointly with a human population PK model for afabicin to predict the efficacy of different clinical dosing regimens (intravenous 55 to 160 mg twice-daily or oral 80 to 240 mg twice-daily) in immunocompetent patients. The developed model included a saturable neutrophil-mediated phagocytosis process of bacteria. The afabicin desphosphono effect was characterized using a model structure previously developed based on in vitro time-kill and neutropenic mouse thigh infection data. A lower maximum killing rate constant (0.24 h −1 ) and an 82% lower EC 50 were estimated for immunocompetent animals compared to in vitro . Predictions indicated that all tested afabicin regimens would achieve bacterial killing in immunocompetent patients infected with S. aureus . Afabicin activity against five S. aureus strains was adequately quantified in immunocompetent animals by the developed PKPD model. Predictions supported the efficacy of afabicin 55 mg intravenously twice daily, followed by an 80 mg oral twice-daily regimen in humans, which is currently tested in a clinical trial in bone and joint infections.